The Effect of Tranexamic Acid on Transfusion Rates in Intertrochanteric Hip Fractures

• Status: Withdrawn
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to determine if the use of tranexamic acid, a safe and effective antifibrinolytic, in patients with intertrochanteric hip fractures will result in a reduction in blood transfusion rates. Treatment will be administered pre-operatively as well as at the time of surgical incision. The primary outcome will be need for blood transfusion. Secondary outcomes will include calculated perioperative blood loss, length of stay, cost of inpatient care, and rate of adverse events, including DVT, PE, infection, MI, cerebrovascular event, need for re-hospitalization or re-operation and 30 day mortality.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital for Special Surgery, New York
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Intertrochanteric Hip Fracture

• Age >18

Exclusion Criteria:

• Preoperative use of anticoagulant (Clopidogrel, Warfarin, Enoxaparin, Fondaparinux, Rivaroxaban

• Allergy to Tranexamic Acid

• History of intracranial hemorrhage or significant GI or retroperitoneal bleed requiring hospitalization

• History of thromboembolic event (Stroke, Deep Vein Thrombosis, Pulmonary Embolism)

• History of cirrhosis or evidence of hepatic (AST/ALT >60) or renal dysfunction (Cr >1.5 or GFR <30)

• Coronary stents or prior diagnosis of CAD

• Color blindness